Literature DB >> 19290019

Definitive radiotherapy with adjuvant long-term antiandrogen treatment for locally advanced prostate cancer: health-related quality of life and hormonal changes.

A Berg1, A A Dahl, Ø S Bruland, T Bjøro, M S Aanensen, S D Fosså.   

Abstract

We assessed self-reported health-related quality of life (HRQoL) and longitudinal changes in sex hormones among 86 prostate cancer (PCa) patients without distant metastases 5 years after radiotherapy (RT) combined with ongoing antiandrogen (AA) treatment. HRQoL outcomes were compared with scores from age-matched controls without a cancer diagnosis (NORM). Compared with NORM, patients scored statistically (P<0.05) and clinically (effect size >or=0.4) lower on sexual domains, and statistically (P<0.05) lower on physical function and vitality. Estimated free testosterone and measured serum estradiol had increased from baseline in most patients, but did not correlate with HRQoL outcomes 5 years after the start of treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19290019     DOI: 10.1038/pcan.2009.8

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  2 in total

1.  Long-term outcomes of intensity-modulated radiation therapy combined with neoadjuvant androgen deprivation therapy under an early salvage policy for patients with T3-T4N0M0 prostate cancer.

Authors:  Takashi Mizowaki; Yoshiki Norihisa; Kenji Takayama; Itaru Ikeda; Haruo Inokuchi; Kiyonao Nakamura; Tomomi Kamba; Takahiro Inoue; Toshiyuki Kamoto; Osamu Ogawa; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2015-07-04       Impact factor: 3.402

Review 2.  Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms.

Authors:  Nadeem Bilani; Hisham Bahmad; Wassim Abou-Kheir
Journal:  Front Pharmacol       Date:  2017-03-21       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.